{"id":"NCT04180488","sponsor":"Sanofi","briefTitle":"Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)","officialTitle":"Master Protocol of Three Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naïve to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-12-11","primaryCompletion":"2024-08-01","completion":"2024-10-25","firstPosted":"2019-11-27","resultsPosted":"2025-08-20","lastUpdate":"2025-08-20"},"enrollment":397,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Spontaneous Urticaria"],"interventions":[{"type":"DRUG","name":"Dupilumab SAR231893","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"non sedating H1-antihistamine","otherNames":[]}],"arms":[{"label":"Study A Dupilumab","type":"EXPERIMENTAL"},{"label":"Study A Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Study B Dupilumab","type":"EXPERIMENTAL"},{"label":"Study B Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Study C Dupilumab","type":"EXPERIMENTAL"},{"label":"Study C Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Primary Objective:\n\nThis study aimed to demonstrate the efficacy of dupilumab in study participants with CSU who remained symptomatic despite the use of H1 antihistamine (Study A and C: omalizumab naïve; Study B: omalizumab intolerant or incomplete responders)\n\nSecondary Objectives:\n\nThis study aimed to demonstrate the efficacy of dupilumab on urticaria activity composite endpoint and itch or hives, separately, at various timepoints This study aimed to demonstrate the efficacy of dupilumab on angioedema This study aimed to demonstrate the efficacy of dupilumab on urticaria control This study aimed to demonstrate improvement in health-related quality of life and overall disease status and severity This study aimed to evaluate the ability of dupilumab in reducing the proportion of participants who require treatment with oral corticosteroids (OCS) This study aimed to evaluate safety outcome measures This study aimed to evaluate immunogenicity of dupilumab","primaryOutcome":{"measure":"Change From Baseline in Weekly Itch Severity Score at Week 24","timeFrame":"Baseline (Day 1) and Week 24","effectByArm":[{"arm":"Study A: Placebo","deltaMin":-6.01,"sd":0.94},{"arm":"Study A: Dupilumab","deltaMin":-10.24,"sd":0.91},{"arm":"Study B: Placebo","deltaMin":-4.81,"sd":1.08},{"arm":"Study B: Dupilumab","deltaMin":-7.68,"sd":1.1},{"arm":"Study C: Placebo","deltaMin":-6.1,"sd":1.4},{"arm":"Study C: Dupilumab","deltaMin":-8.64,"sd":1.41}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0005"},{"comp":"OG002 vs OG003","p":"0.0449"},{"comp":"OG004 vs OG005","p":"0.0184"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":12},"locations":{"siteCount":98,"countries":["United States","Argentina","Canada","China","France","Germany","Hungary","Japan","Russia","Spain","United Kingdom"]},"refs":{"pmids":["39066978"],"seeAlso":["https://sanofi.trialsummaries.com/Study/StudyDetails?id=25248&tenant=MT_SNY_9011"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":68},"commonTop":["Chronic Spontaneous Urticaria","Covid-19","Nasopharyngitis","Injection Site Erythema","Accidental Overdose"]}}